Karamjit Singh Maniani
About Karamjit Singh Maniani
Karamjit Singh Maniani is a Senior Specialist (MES) Project Lead at Bristol Myers Squibb with a diverse background in the pharmaceutical industry and a strong educational foundation in biological sciences and pharmaceutical business.
Current Role at Bristol Myers Squibb
Karamjit Singh Maniani currently holds the position of Senior Specialist (MES) Project Lead at Bristol Myers Squibb. He is responsible for overseeing manufacturing execution systems (MES) projects, ensuring that they meet the company's standards and objectives. His role involves coordinating across various departments to streamline processes and enhance efficiency in manufacturing operations.
Previous Experience at Adaptimmune
From 2020 to 2021, Karamjit Singh Maniani worked at Adaptimmune as a Manufacturing Cell Therapy Specialist. In this role, he specialized in the production of cell therapies, focusing on maintaining high standards of quality and compliance in manufacturing practices. His experience here contributed significantly to his understanding of advanced therapeutic production processes.
Education and Academic Background
Karamjit Singh Maniani has an extensive educational background that combines life sciences and business. He earned a Master of Business Administration (MBA) in Pharmaceutical and Healthcare Business from the University of the Sciences in Philadelphia. Additionally, he holds a Bachelor's of Science in Biology/Biological Sciences from Rowan University. His academic achievements have equipped him with a unique blend of expertise in both the scientific and business aspects of the pharmaceutical industry.
Career in Pharmaceutical Industry
Karamjit Singh Maniani has held various positions within the pharmaceutical industry, showcasing his diverse skill set. His roles have included a Manufacturing Associate Upstream Contractor at Bristol-Myers Squibb, a Safety & Pharmacovigilance Coordinator II at Syneos Health, and a Manufacturing Cell Therapy Specialist at Adaptimmune. Through these roles, he has gained extensive experience in cell therapy manufacturing, pharmacovigilance, and upstream manufacturing processes.